<DOC>
	<DOCNO>NCT00907036</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . Also , monoclonal antibody , alemtuzumab , find cancer cell either kill deliver cancer-killing substance without harm normal cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine transplant may stop happen . Once donated stem cell begin work , patient 's immune system may see remain cancer cell belong patient 's body destroy ( call graft-versus-tumor effect ) . Giving infusion donor 's white blood cell ( donor lymphocyte infusion ) may boost effect . PURPOSE : This phase II trial study side effect fludarabine phosphate , melphalan , alemtuzumab follow donor stem cell transplant treat patient relapse Hodgkin lymphoma .</brief_summary>
	<brief_title>Fludarabine Phosphate , Melphalan , Alemtuzumab Followed Donor Stem Cell Transplant Treating Patients With Relapsed Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - To document toxicity , feasibility , survival reduced-intensity conditioning follow allogeneic hematopoietic stem cell transplantation match sibling donor patient relapse , chemosensitive Hodgkin lymphoma . OUTLINE : This multicenter study . - Reduced-intensity conditioning : Patients receive fludarabine phosphate IV day -7 -3 , melphalan IV 30 minute day -2 , alemtuzumab IV day -1 . - Transplantation : Patients undergo donor stem cell infusion day 0 . - Graft-vs-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV orally day -1 60 , follow taper 3 month post-transplantation , absence GVHD . - Donor-lymphocyte infusion ( DLI ) : DLI use eradication mixed chimerism management residual relapse disease . If necessary , patient undergo DLI every 3 month desire endpoint achieve GVHD develops . After completion study therapy , patient follow every 3 month 3 year . This study peer review funded endorsed Cancer Research UK .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis Hodgkin lymphoma , meet follow criterion : Achieved partial complete remission ( use standard criterion ) salvage chemotherapy Relapsed first remission residual fludeoxyglucose F 18avid lesion Available HLAmatched sibling donor PATIENT CHARACTERISTICS : WHO performance status 01 Creatinine clearance ≥ 50 mL/min ( measure EDTA clearance 24hour urine collection ) Serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2 time ULN LVEF ≥ 40 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month ( 3 month woman ) completion study therapy No malignancy within past 5 year except nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma No HIV positivity No symptomatic respiratory compromise No concurrent serious medical condition would preclude transplantation PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior highdose therapy allograft</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
</DOC>